Dysregulation of microRNAs in triple-negative breast cancer

Abstract

Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and poor prognosis. TNBC is usually diagnosed at a relatively young age and is characterized by high risk of developing metastases. Some epigenetic regulation of gene expression is associated with TNBC. Expression of microRNAs (miRNAs) can serve as a potential tool for identifying critical biomarkers in TNBC.The aim of our study is to examine expression of selected miRNAs in TNBC and to assess the relationship between miRNA expression and clinicopathological factors. Material and methods:Expression levels of 19 selected miRNAs were compared between cancerous and normal breast tissues by use of qPCR method. We have evaluated the relationship between the expression level of miRNAs and clinicopathological factors such as: age, tumor size and lymph node status. Results:We found that in TNBC tissues, when compared with normal breast tissues, the expression of miR-190a, miR-136-5p and miR-126-5p was significantly reduced (p = 0.0041, p = 0.0007, p = 0.0007, respectively) whereas expression of miR-135b-5p and miR-182-5p was significantly increased (p = 0.0194, p = 0.0041, respectively). We found a linear trend for tumor size and expression of miR-126-5p (p = 0.0296) and miR-135b-5p (p = 0.0241). Conclusions:Our study confirms that miRNA expression profile is dysregulated in TNBC patients compared to healthy controls. and miR-182-5p may be associated with development and progression of TNBC.

Identification of dysregulated miRNAs in triple negative breast cancer: A meta‐analysis approach

“…Moreover, it promotes tumor invasion and metastasis by regulating RECK (reversion‐inducing‐cysteine‐rich) and EVI5 (ecotrophic viral integration site 5) in hepatocellular carcinoma (Y. Li et al, ). Also, mir‐135b expression is found to be high when compared with normal breast tissue, suggesting that it might be associated with development and progression of TNBC (Paszek et al, ). Hsa‐miR‐18a promotes hepatocellular carcinoma cell migration and invasion by directly targeting Dicer 1 in vitro (X. Zhang, Yu, Zhang, Guo, & Li, ).…”

Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status

“…BRCA1 is a tumor suppressor gene which, when mutated, is associated with a high sensitivity to breast cancer (Tanic et al, ). Several studies investigated the expression profile of miRNAs in TNBC tissues in comparison to the normal tissues (Paszek et al, ; Radojicic et al, ). In the present study, we explored the expression level of 667 microRNAs in TNBC tissues and compared it to that of normal tissues using TLDA.…”

“…vs normal tissues and showed that expression of some miRNAs plays a significant role in triple-negative primary breast cancers (Paszek et al, 2017;Radojicic et al, 2011). In this study, we screened the expression level of 667 different human miRNAs in TNBC tissues having wild type and mutated BRCA1 and normal breast tissues.…”

“…In breast cancer, several molecular miRNA signatures of various subtypes of breast cancer have been suggested (Adhami, Haghdoost, Sadeghi, & Malekpour, ; Ohzawa et al, ). Previous reports studied the expression level of miRNAs in TNBC vs normal tissues and showed that expression of some miRNAs plays a significant role in triple‐negative primary breast cancers (Paszek et al, ; Radojicic et al, ). In this study, we screened the expression level of 667 different human miRNAs in TNBC tissues having wild type and mutated BRCA1 and normal breast tissues.…”

MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance, and Applications in Human Triple-Negative Breast Cancer

“…The dysregulation of miRNAs are involved in different cancer pathogenesis of solid tumors, such as apoptosis, inflammation, stress response, cell cycle, proliferation; the tumor microenvironment facilitates tumor development, differentiation, morphogenesis, progression and metastasis, and acted either in dominant or recessive roles, including breast cancer [16][17][18]. Emerging in vitro and in vivo studies open up a new area that miRNAs have the potential to serve as promising biomarkers for diagnosis and the development of novel anticancer drugs [19]. In this review, we attempt to summarize the potential clinical value and the roles of miRNAs involved in the pathogenesis of TNBC, such as the regulation of epigenetic mechanisms, epithelial-to-mesenchymal transition (EMT), maintenance of stemness, proliferation, metastasis, and apoptosis.…”